ArticlePloS one2012
Reproducibility, performance, and clinical utility of a genetic risk prediction model for prostate cancer in Japanese.
Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Multigene panels in prostate cancer risk assessment: a systematic review.Genetics in medicine : official journal of the American College of Medical Genetics · 2016Pooled it
- Population-standardized genetic risk score: the SNP-based method of choice for inherited risk assessment of prostate cancer.Asian journal of andrologyTrial
- Polygenic risk and germline genetics for prostate cancer in Asians: Where do we stand?Investigative and clinical urology · 2026Review
- Polygenic risk score for tumor aggressiveness and early-onset prostate cancer in Asians.Scientific reports · 2023Article
- Clinical Utility of Germline Genetic Testing in Japanese Men Undergoing Prostate Biopsy.JNCI cancer spectrum · 2022Article
- Prediction of clinically significant prostate cancer using polygenic risk models in Asians.Investigative and clinical urology · 2022Article
- Polygenic risk score for genetic evaluation of prostate cancer risk in Asian populations: A narrative review.Investigative and clinical urology · 2021Review
- Review
- Clinical outcomes and prognostic factors in patients with newly diagnosed metastatic prostate cancer initially treated with androgen deprivation therapy: a retrospective multicenter study in Japan.International journal of clinical oncology · 2020Article
- 12 new susceptibility loci for prostate cancer identified by genome-wide association study in Japanese population.Nature communications · 2019Article
- Assessing the performance of genome-wide association studies for predicting disease risk.PloS one · 2019Article
- A novel model to predict positive prostate biopsy based on serum androgen level.Endocrine-related cancer · 2018Article
- An Integrative Genomics Approach for Associating Genome-Wide Association Studies Information With Localized and Metastatic Prostate Cancer Phenotypes.Biomarker insights · 2017Article
- Adding genetic risk score to family history identifies twice as many high-risk men for prostate cancer: Results from the prostate cancer prevention trial.The Prostate · 2016Article
- The PROFILE Feasibility Study: Targeted Screening of Men With a Family History of Prostate Cancer.The oncologist · 2016Article
- Article
- The moral concerns of biobank donors: the effect of non-welfare interests on willingness to donate.Life sciences, society and policy · 2016Article
- Incorporation of detailed family history from the Swedish Family Cancer Database into the PCPT risk calculator.The Journal of urology · 2015Article
- A genetic-based approach to personalized prostate cancer screening and treatment.Current opinion in urology · 2015Review
- Plateau effect of prostate cancer risk-associated SNPs in discriminating prostate biopsy outcomes.The Prostate · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
Prostate specific antigen (PSA) is widely used as a diagnostic biomarker for prostate cancer (PC). However, due to its low predictive performance, many patients without PC suffer from the harms of unnecessary prostate needle biopsies. The present study aims to evaluate the reproducibility and performance of a genetic risk prediction model in Japanese and estimate its utility as a diagnostic biomarker in a clinical scenario. We created a logistic regression model incorporating 16 SNPs that were significantly associated with PC in a genome-wide association study of Japanese population using 689 cases and 749 male controls. The model was validated by two independent sets of Japanese samples comprising 3,294 cases and 6,281 male controls. The areas under curve (AUC) of the model were 0.679, 0.655, and 0.661 for the samples used to create the model and those used for validation. The AUCs were not significantly altered in samples with PSA 1-10 ng/ml. 24.2% and 9.7% of the patients had odds ratio <0.5 (low risk) or >2 (high risk) in the model. Assuming the overall positive rate of prostate needle biopsies to be 20%, the positive biopsy rates were 10.7% and 42.4% for the low and high genetic risk groups respectively. Our genetic risk prediction model for PC was highly reproducible, and its predictive performance was not influenced by PSA. The model could have a potential to affect clinical decision when it is applied to patients with gray-zone PSA, which should be confirmed in future clinical studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.